You are here
Dosing and Safety Implications for Oncologists When Administering Everolimus to Patients With Hormone Receptor-Positive Breast Cancer
Hope S. RugoClinical Breast Cancer, Vol. 16, No. 1, 18-22
Presentation by Dr. Laurent Zelek at the TAO Congress on 19/20 November 2015Treatment-induced toxicities represent a major problem in cancer therapy. Toxicities which cannot be managed by curative treatment or supportive care...
Presentation by Dr. Jean-Yves Pierga at the TAO Congress on 19/20 November 2015The first presentation of the session dedicated to “New therapies and supportive care in breast cancer” is by Dr. Jean-Yves...
Presentation by Dr. Benjamin Besse at the TAO Congress on 19/20 November 2015Dr. Benjamin Besse is Head of the Thoracic Unit at the cancer-research institute and oncology health centre Institut Gustave Roussy...
Presentation by Dr. Capucine Morelot at the TAO Congress on 19/20 November 2015According to the definition in the 1999 consensus statement of the American Thoracic Society, dyspnoea is “a subjective experience of...
mTOR inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm
Willemsen AE, Grutters JC, Gerritsen WR, van Erp NP, van Herpen CM, Tol J.Int J Cancer. 2015 Oct 9. doi: 10.1002/ijc.29887. [Epub ahead of print]Topic: Lung toxicity
Sheikh A. Saleem, Nischala Ammannagari, Amanda R. McFee Winans and James M. LeonardoGlobal Journal of Hematology and Blood Transfusion, 2015, 2, 1-3Topic: Lung toxicity
- Radiation increases the risk of developing cardiac diseases, particularly ischemic heart disease, and there is also concern about the radiation...Category: Interviews
Exercise intervention for patients surgically treated for Non-Small Cell Lung Cancer (NSCLC): A systematic review
Katy Crandall, Roma Maguire, Anna Campbell, Nora Kearney
Surgical Oncology, 1, 23, pages 17 - 30